Cure My Disease

Don't miss your cure!

 Log in / Sign up

New Antibody-Drug cocktail targets tough colorectal cancer

NCT ID NCT07503756

Recruiting now Disease control Sponsor: Shanghai Junshi Bioscience Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new drug called JS212, which is designed to target two proteins on cancer cells (EGFR and HER3) and deliver a chemotherapy-like payload directly to them. It is being tested in combination with other standard cancer drugs in 80 adults with metastatic colorectal cancer that has not been treated before. The goal is to see if these combinations are safe and can shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
JS212 (bispecific antibody-drug conjugate targeting EGFR and HER3) combined with capecitabine, bevacizumab, oxaliplatin, and/or JS207
What this could lead to
If successful, this could lead to a new treatment option for people with metastatic colorectal cancer that has not spread after initial therapy.
What could go wrong
This is an early Phase 2 trial with only 80 participants, so results may not apply to everyone. The combination therapies may cause side effects or not work better than existing treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC COLORECTAL ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

colorectal adenocarcinoma colorectal cancer colorectal neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

METASTATIC COLORECTAL CANCER

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai East Hospital

    RECRUITING

    Shanghai, Shanghai Municipality, 200123, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.